色素沈着症治療市場 - 世界の産業規模、シェア、動向、機会、予測、2018-2028年、適応症別、治療・動向別、エンドユーザー別、地域別、競合

世界の色素沈着症治療市場は、2022年に61億米ドルと評価され、2028年までのCAGRは6.80%で、予測期間中に目覚ましい成長を示すと予測されています。

色素沈着症は、色素異常症または色素過剰／色素沈着過剰症としても知られ、皮膚の色調に影響を及ぼす疾患です。これらの疾患は、皮膚の色素沈着に不規則性をもたらし、周囲の領域よりも暗い（色素沈着）または明るい（色素沈着低下）皮膚の斑点をもたらします。色素沈着症は、遺伝、日光暴露、炎症、ホルモンの変化、基礎疾患など、さまざまな要因によって引き起こされる可能性があります。色素沈着症は多くの人にとって美容上の悩みの種であり、あらゆる年齢や肌質の人に影響を及ぼす可能性があります。治療の選択肢は、色素沈着症の種類と重症度によって異なり、外用剤、ケミカルピーリング、レーザー治療、マイクロダーマブレーション、場合によっては外科的処置が含まれます。

世界の高齢化が色素沈着症治療の需要を牽引しています。色素沈着の問題はしばしば皮膚の老化と関連しており、こうした懸念に対処する治療への関心が高まっています。色素沈着症は、人の外見や自尊心に大きな影響を与える可能性があります。透明感のある均一な肌色への願望は、色素沈着治療を求める人々の強い原動力となっています。皮膚科学技術と治療法の進歩により、効果的な治療法の幅が広がっています。レーザー治療、ケミカルピーリング、マイクロダーマブレーションは、市場成長を牽引する革新的技術の一例です。教育キャンペーンやデジタルメディアによって、色素沈着症や利用可能な治療オプションに対する消費者の意識が高まり、色素沈着治療に対する需要が高まっています。ハイドロキノン、レチノイド、ナイアシンアミドなどの成分を含む、色素沈着症専用に処方された外用剤やスキンケア製品の市場開拓は、治療の選択肢を広げ、市場成長に貢献しています。

主要市場促進要因

技術の進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の色素沈着症治療市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 適応症別（色素沈着症、色素沈着症）
  • 治療別（ケミカルピーリング、皮膚剥離、レーザーリサーフェシング、肝斑）
  • エンドユーザー別（皮膚科クリニック、病院）
  • 企業別（2022年）
• 市場マップ

第6章 アジア太平洋地域の色素沈着症治療市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 適応症別
  • 治療別
  • エンドユーザー別
  • 国別
• アジア太平洋地域国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州の色素沈着症治療市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 適応症別
  • 治療別
  • エンドユーザー別
  • 国別
• 欧州国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米の色素沈着症治療市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 適応症別
  • 治療別
  • エンドユーザー別
  • 国別
• 北米国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米の色素沈着症治療市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 適応症別
  • 治療別
  • エンドユーザー別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの色素沈着症治療市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 適応症別
  • 治療別
  • エンドユーザー別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界の色素沈着症治療市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 PESTLE分析

第16章 競合情勢

• Zerigo Health.
• Bausch Health Companies Inc.
• Glenmark Pharmaceuticals Limited
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Bayer AG
• CLINUVEL PHARMACEUTICALS LTD
• Strides Pharma Science Limited
• Astellas Pharma Inc.

第17章 戦略的提言

第18章 調査会社・免責事項

Global Pigmentation Disorders Treatment Market has valued at USD 6.10 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 6.80% through 2028. Pigmentation disorders, also known as dyschromia or hyperpigmentation/hypopigmentation disorders, are conditions that affect the coloration of the skin. These disorders result in irregularities in the pigmentation of the skin, leading to patches of skin that are darker (hyperpigmentation) or lighter (hypopigmentation) than the surrounding areas. Pigmentation disorders can be caused by various factors, including genetics, sun exposure, inflammation, hormonal changes, and underlying medical conditions. Pigmentation disorders can be a source of cosmetic concern for many individuals, and they can affect people of all ages and skin types. Treatment options vary depending on the type and severity of the pigmentation disorder and may include topical agents, chemical peels, laser therapy, microdermabrasion, and in some cases, surgical procedures.

The global aging population is driving the demand for pigmentation disorder treatments. Pigmentation issues are often associated with aging skin, leading to increased interest in treatments to address these concerns. Pigmentation disorders can have a significant impact on a person's appearance and self-esteem. The desire for clear and even skin tone is a strong driver for individuals seeking pigmentation treatment. Advances in dermatological technologies and treatment options have expanded the range of effective treatments available. Laser therapy, chemical peels, and microdermabrasion are examples of innovative technologies driving market growth. Increased consumer awareness about pigmentation disorders and available treatment options, driven by educational campaigns and digital media, has led to a higher demand for pigmentation treatments. The development of topical agents and skincare products formulated specifically for pigmentation disorders, containing ingredients like hydroquinone, retinoids, and niacinamide, has expanded treatment options and contributed to market growth.

Key Market Drivers

Technological Advancements

Laser technology has seen significant advancements in the treatment of pigmentation disorders. Different types of lasers, such as Q-switched lasers, fractional lasers, and picosecond lasers, have been developed to target specific pigmentation issues. These lasers offer precise control and reduced risk of scarring compared to earlier laser technologies. IPL (Intense Pulsed Light) devices use a broad spectrum of light to target pigmentation issues like sunspots and age spots. Modern IPL devices have become more efficient and customizable, allowing dermatologists to tailor treatments to individual skin types and conditions. Fractional Radiofrequency (RF) devices combine radiofrequency energy with micro needling to stimulate collagen production and improve skin texture, including pigmentation disorders. These devices offer a non-invasive approach with minimal downtime. Formulations of topical agents have improved through nanotechnology and advanced ingredient delivery systems. These formulations enhance the penetration of active ingredients into the skin, increasing their efficacy in treating pigmentation issues. Cryotherapy involves the application of extreme colds to target and remove pigmented lesions. Advanced cryotherapy devices offer precise control and minimize damage to surrounding healthy tissue. Picosecond lasers deliver ultra-short pulses of laser energy, which are highly effective in breaking down pigmented lesions. This technology has been particularly useful in the treatment of stubborn pigmentation disorders.

Three-dimensional skin imaging technology allows dermatologists to assess pigmentation disorders and track treatment progress more accurately. It provides a detailed view of skin conditions at different depths. Artificial intelligence (AI) and machine learning algorithms are being employed in dermatology to assist in the diagnosis of pigmentation disorders and to recommend personalized treatment plans. These technologies improve accuracy and efficiency in patient care. Advances in telemedicine have made it easier for patients to consult with dermatologists remotely. Teledermatology platforms allow dermatologists to assess pigmentation issues and recommend treatment options without in-person visits. Technological tools, such as skin analyzers and computer simulations, help dermatologists create customized treatment plans for patients with pigmentation disorders. These plans consider individual skin types and the specific pigmentation issue being addressed. Dermoscopy involves the use of specialized magnifying devices and digital imaging to examine pigmented skin lesions in detail. It aids in the early diagnosis of pigmentation disorders and melanoma. Some pigmentation disorders treatment technologies originally developed for tattoo removal, such as Q-switched lasers, have been adapted for addressing pigmented skin lesions, offering more precise and effective treatments. This factor will help in the development of Global Pigmentation Disorders Treatment Market.

Rising Aging Population

Pigmentation disorders, such as age spots (lentigines) and melasma, are more common among older individuals. As people age, they are more likely to develop these skin concerns, leading to a higher demand for treatment. Aging is associated with changes in the skin, including reduced collagen production, thinning of the epidermis, and decreased skin cell turnover. These changes can make the skin more susceptible to pigmentation issues, prompting older individuals to seek treatment to address age-related skin concerns. Over a lifetime, exposure to ultraviolet (UV) radiation from the sun can lead to the accumulation of sun damage and pigmentation irregularities. As individuals age, the effects of cumulative sun exposure become more apparent, leading to an increased desire to correct pigmentation issues.

Many older individuals are interested in maintaining a youthful appearance and addressing the visible signs of aging, including pigmentation disorders. Treating these concerns can improve overall skin tone and enhance one's appearance. Pigmentation disorders can have a significant impact on an individual's self-esteem and self-confidence, regardless of age. Older adults may place a higher value on addressing these concerns to maintain a positive self-image. Advances in dermatological technologies and treatments have made it possible to effectively address pigmentation disorders, even in older individuals. These advancements have led to safer and more efficient treatment options. The aging population is generally more health-conscious and informed about skincare and dermatological treatments. This awareness contributes to a greater willingness to seek pigmentation disorder treatments. Some older individuals may travel to other regions or countries for medical treatments, including pigmentation disorder treatments, to access high-quality care at a lower cost. Aesthetic and dermatological treatments, including those for pigmentation disorders, can enhance an individual's quality of life by improving self-confidence and overall well-being. This motivates many older adults to seek these treatments. Older adults may adopt preventive skincare measures to minimize the development of new pigmentation issues, further driving the demand for pigmentation disorder treatments. This factor will pace up the demand of Global Pigmentation Disorders Treatment Market.

Growing Demand of Topical Agents and Skincare Products

Topical agents and skincare products play a crucial role in driving the demand for pigmentation disorders treatment. These products are popular among individuals seeking non-invasive and over-the-counter solutions for addressing pigmentation issues. Topical agents and skincare products are readily accessible to consumers without the need for a prescription. This accessibility makes them an attractive option for individuals looking to address pigmentation concerns independently. Many people prefer non-invasive treatments for pigmentation disorders, and topical agents fall into this category. They do not require needles, lasers, or surgical procedures, making them less intimidating for individuals seeking treatment. Topical agents are typically easy to incorporate into a daily skincare routine. Consumers can apply these products at home, which adds to their convenience and attractiveness. The market offers a wide variety of topical agents and skincare products formulated to target pigmentation disorders. These products often contain active ingredients like hydroquinone, retinoids, kojic acid, niacinamide, and vitamin C, which are known for their efficacy in reducing pigmentation irregularities. Topical agents and skincare products can work through various mechanisms to address pigmentation issues. Some products inhibit melanin production, while others promote exfoliation or target specific pigmented areas. Dermatologists often recommend combination therapies that include topical agents alongside other treatments like laser therapy or chemical peels. This combination approach can enhance treatment outcomes. Skincare products formulated for pigmentation disorders are not only used for treatment but also for maintenance and prevention. Individuals may continue to use these products to maintain the results of their treatments and prevent the recurrence of pigmentation issues.

Many topical agents and skincare products produce gradual improvements in pigmentation, which can be preferable for individuals who want to achieve more subtle and natural-looking results. Compared to some medical procedures and treatments, topical agents and skincare products are often more cost-effective. This makes them an attractive option for individuals on a budget. Skincare products can be formulated to address different skin types and tones, allowing a broad range of individuals to find suitable products for their specific needs. Advertising, marketing efforts, and educational campaigns have increased consumer awareness about the effectiveness of topical agents and skincare products in treating pigmentation disorders. Unlike some medical procedures, the use of topical agents and skincare products typically involves little to no downtime, allowing individuals to continue their daily activities. This factor will accelerate the demand of Global Pigmentation Disorders Treatment Market.

Key Market Challenges

Cost of Treatment

The cost of pigmentation disorder treatment can vary widely depending on factors such as the type and severity of the condition, the treatment method chosen, the geographical location of the healthcare facility, and the expertise of the healthcare provider. Some treatments, such as laser therapy or combination therapies, can be relatively expensive. In many cases, multiple treatment sessions are required to achieve the desired results. Each session may come with its associated cost, including consultation fees, treatment fees, and follow-up appointments. Not all pigmentation disorder treatments are covered by medical insurance plans, especially if the treatment is considered cosmetic in nature. This can place the financial burden squarely on the patient. Patients often must bear out-of-pocket expenses for treatments, including co-pays, deductibles, and prescription costs. These expenses can add up, particularly for long-term or recurrent treatments. While over-the-counter skincare products are accessible and affordable for some, there is a market for high-end, prescription-grade skincare products formulated for pigmentation disorders. These products can be costly. Patients who seek specialized treatments from renowned dermatologists or skincare clinics may incur travel expenses, including transportation, accommodation, and meals, which can significantly increase the overall cost of treatment. Pigmentation disorder treatments often require follow-up appointments and maintenance procedures to sustain results. These ongoing costs can be a challenge for patients.

Limited Efficacy of Current Treatments

Pigmentation disorders can vary in their underlying causes and mechanisms. Some disorders are related to excessive melanin production, while others result from a loss of melanocytes. Treating these diverse conditions with a one-size-fits-all approach can be challenging. In some cases, pigmentation disorders may not respond well to standard treatments. For example, certain types of melasma can be resistant to traditional therapies like topical agents, making it difficult to achieve desired results. Some pigmentation disorders, such as melasma and post-inflammatory hyperpigmentation, can be chronic and prone to recurrence, even after successful treatment. This necessitates ongoing management and maintenance. Some treatments for pigmentation disorders, such as laser therapy and chemical peels, carry the risk of side effects, including skin irritation, scarring, and hyperpigmentation (post-inflammatory hyperpigmentation) if not performed correctly. These risks can limit treatment options for some individuals. The response to treatment can vary from person to person due to factors like skin type, genetics, and individual skin sensitivities. What works well for one individual may not yield the same results for another. Pigmentation disorders may not always completely clear with treatment, leaving residual discoloration or uneven skin tone. Achieving full clearance can be challenging. Melasma is known for its complex nature. It often requires a combination of treatments and strict sun protection to manage effectively, and complete clearance may not always be achievable.

Key Market Trends

Personalized Medicine

Personalized medicine allows healthcare providers to develop treatment plans that are customized to the specific type and severity of pigmentation disorder a patient has. This approach considers factors such as the patient's skin type, genetics, lifestyle, and response to previous treatments. Advancements in genetic and molecular analysis have provided insights into the genetic factors underlying pigmentation disorders. Genetic testing and analysis can help identify specific gene mutations or variations that may contribute to the condition, enabling more targeted treatment strategies. Pharmacogenomics is the study of how an individual's genetic makeup affects their response to medications. In the context of pigmentation disorders treatment, pharmacogenomic testing can help determine which topical agents or medications are most likely to be effective for a particular patient, reducing the trial-and-error approach to treatment. Personalized medicine considers an individual's skin type, including factors like skin color, sensitivity, and pigmentation characteristics. This information guides treatment decisions, as different skin types may respond differently to treatments. Personalized medicine often involves combining different treatment modalities to address pigmentation disorders comprehensively. For example, a personalized treatment plan may include a combination of topical agents, laser therapy, and chemical peels tailored to the patient's specific needs. Advancements in laser technology allow for more precise and targeted treatment of pigmentation disorders. Lasers can be adjusted to specific wavelengths and intensities based on the patient's skin type and pigmentation issue. Personalized medicine encourages patient engagement and participation in treatment decisions. Educating patients about their condition and treatment options empowers them to make informed choices.

Segmental Insights

Indication Insights

In 2022, the Global Pigmentation Disorders Treatment Market largest share was held by Hyperpigmentation segment and is predicted to continue expanding over the coming years. Hyperpigmentation disorders, such as melasma, post-inflammatory hyperpigmentation, and age spots, are relatively common skin conditions. They affect a large portion of the population, making them a significant market segment in terms of patient demand for treatment. Sun exposure is a major contributor to hyperpigmentation. As people become more aware of the importance of sun protection and skincare, the demand for treatments to address existing hyperpigmentation issues may increase. Hyperpigmentation is often a cosmetic concern for individuals, as it can affect their appearance and self-confidence. Many people seek treatment to achieve a more even skin tone and reduce the visible signs of hyperpigmentation. There is a wide range of treatment options available for hyperpigmentation, including topical creams, chemical peels, laser therapy, and microdermabrasion. This diversity of treatment modalities allows healthcare providers to tailor treatment plans to individual patient needs.

Treatment & Therapies Insights

In 2022, the Global Pigmentation Disorders Treatment Market largest share was held by Dermabrasion segment and is predicted to continue expanding over the coming years. Dermabrasion has a history of being effective in improving skin texture and addressing certain pigmentation issues. It can help reduce the appearance of scars, uneven skin tone, and some types of hyperpigmentation. Dermabrasion can be used to treat a range of skin concerns beyond pigmentation disorders, such as acne scars, fine lines, and wrinkles. Its versatility makes it a popular choice among dermatologists and patients. Compared to certain other pigmentation treatment methods like laser therapy, dermabrasion may have a shorter recovery time, making it a more attractive option for individuals with busy lifestyles. Dermabrasion procedures are often available at dermatology clinics and medical spas, making them accessible to a wide range of patients.

End User Insights

In 2022, the Global Pigmentation Disorders Treatment Market largest share was held by Dermatology Clinics segment in the forecast period and is predicted to continue expanding over the coming years. Dermatology clinics are staffed by dermatologists who specialize in the diagnosis and treatment of skin disorders, including pigmentation disorders. Patients often seek care from dermatologists for accurate diagnosis and personalized treatment plans. Dermatology clinics typically have access to state-of-the-art equipment and technologies for diagnosing and treating pigmentation disorders. This can include laser therapy devices, microdermabrasion machines, and other advanced tools. Dermatology clinics offer a comprehensive range of services for various skin conditions, including pigmentation disorders. Patients can receive treatments like laser therapy, chemical peels, topical agents, and dermabrasion all in one location. Some pigmentation disorder treatments, such as laser therapy and chemical peels, require medical supervision. Dermatology clinics provide a controlled and safe environment for these treatments.

Regional Insights

The North America region dominates the Global Pigmentation Disorders Treatment Market in 2022. North America, particularly the United States and Canada, boasts a highly developed healthcare infrastructure with many dermatology clinics, hospitals, and medical facilities specializing in skincare and dermatological treatments. The United States has one of the highest healthcare spending levels in the world. This translates into greater accessibility to healthcare services and treatments for various conditions, including pigmentation disorders. North America is a hub for medical research and technological advancements in the field of dermatology. The region is often at the forefront of adopting new and innovative pigmentation disorder treatment technologies and techniques. The population in North America is generally well-informed about skincare and pigmentation disorders, and there is a significant demand for cosmetic and dermatological treatments to address these concerns.

Key Market Players

• Zerigo Health.

• Bausch Health Companies Inc.

• Glenmark Pharmaceuticals Limited

• Novartis AG

• Pfizer Inc.

• Teva Pharmaceutical Industries Ltd

• Bayer AG

• CLINUVEL PHARMACEUTICALS LTD

• Strides Pharma Science Limited

• Astellas Pharma Inc.

Report Scope:

In this report, the Global Pigmentation Disorders Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pigmentation Disorders Treatment Market, By Indication:

• Hyperpigmentation
• Hypopigmentation

Pigmentation Disorders Treatment Market, By Treatment & Therapies:

• Chemical Peels
• Dermabrasion
• Laser Resurfacing
• Melasma

Pigmentation Disorders Treatment Market, By End User:

• Dermatology Clinics
• Hospitals

Global Pigmentation Disorders Treatment Market, By region:

• North America
• United States
• Canada
• Mexico
• Asia-Pacific
• China
• India
• South Korea
• Australia
• Japan
• Europe
• Germany
• France
• United Kingdom
• Spain
• Italy
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Pigmentation Disorders Treatment Market.

Available Customizations:

• Global Pigmentation Disorders Treatment Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pigmentation Disorders Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Indication (Hyperpigmentation, Hypopigmentation)
  • 5.2.2. By Treatment & Therapies (Chemical Peels, Dermabrasion, Laser Resurfacing, Melasma)
  • 5.2.3. By End User (Dermatology Clinics, Hospitals),
  • 5.2.4. By Company (2022)
• 5.3. Market Map

6. Asia Pacific Pigmentation Disorders Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Indication
  • 6.2.2. By Treatment & Therapies
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Pigmentation Disorders Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Indication
      • 6.3.1.2.2. By Treatment & Therapies
      • 6.3.1.2.3. By End User
  • 6.3.2. India Pigmentation Disorders Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Indication
      • 6.3.2.2.2. By Treatment & Therapies
      • 6.3.2.2.3. By End User
  • 6.3.3. Australia Pigmentation Disorders Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Indication
      • 6.3.3.2.2. By Treatment & Therapies
      • 6.3.3.2.3. By End User
  • 6.3.4. Japan Pigmentation Disorders Treatment Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Indication
      • 6.3.4.2.2. By Treatment & Therapies
      • 6.3.4.2.3. By End User
  • 6.3.5. South Korea Pigmentation Disorders Treatment Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Indication
      • 6.3.5.2.2. By Treatment & Therapies
      • 6.3.5.2.3. By End User

7. Europe Pigmentation Disorders Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Indication
  • 7.2.2. By Treatment & Therapies
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Pigmentation Disorders Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Indication
      • 7.3.1.2.2. By Treatment & Therapies
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Pigmentation Disorders Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Indication
      • 7.3.2.2.2. By Treatment & Therapies
      • 7.3.2.2.3. By End User
  • 7.3.3. Spain Pigmentation Disorders Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Indication
      • 7.3.3.2.2. By Treatment & Therapies
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Pigmentation Disorders Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Indication
      • 7.3.4.2.2. By Treatment & Therapies
      • 7.3.4.2.3. By End User
  • 7.3.5. United Kingdom Pigmentation Disorders Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Indication
      • 7.3.5.2.2. By Treatment & Therapies
      • 7.3.5.2.3. By End User

8. North America Pigmentation Disorders Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Indication
  • 8.2.2. By Treatment & Therapies
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Pigmentation Disorders Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Indication
      • 8.3.1.2.2. By Treatment & Therapies
      • 8.3.1.2.3. By End User
  • 8.3.2. Mexico Pigmentation Disorders Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Indication
      • 8.3.2.2.2. By Treatment & Therapies
      • 8.3.2.2.3. By End User
  • 8.3.3. Canada Pigmentation Disorders Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Indication
      • 8.3.3.2.2. By Treatment & Therapies
      • 8.3.3.2.3. By End User

9. South America Pigmentation Disorders Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Indication
  • 9.2.2. By Treatment & Therapies
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Pigmentation Disorders Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Indication
      • 9.3.1.2.2. By Treatment & Therapies
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Pigmentation Disorders Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Indication
      • 9.3.2.2.2. By Treatment & Therapies
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Pigmentation Disorders Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Indication
      • 9.3.3.2.2. By Treatment & Therapies
      • 9.3.3.2.3. By End User

10. Middle East and Africa Pigmentation Disorders Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Indication
  • 10.2.2. By Treatment & Therapies
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Pigmentation Disorders Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Indication
      • 10.3.1.2.2. By Treatment & Therapies
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Pigmentation Disorders Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Indication
      • 10.3.2.2.2. By Treatment & Therapies
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Pigmentation Disorders Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Indication
      • 10.3.3.2.2. By Treatment & Therapies
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Pigmentation Disorders Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Zerigo Health.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Bausch Health Companies Inc.
  • 16.2.1. Business Overview
  • 16.2.2. Company Snapshot
  • 16.2.3. Products & Services
  • 16.2.4. Financials (In case of listed companies)
  • 16.2.5. Recent Developments
  • 16.2.6. SWOT Analysis
• 16.3. Glenmark Pharmaceuticals Limited
  • 16.3.1. Business Overview
  • 16.3.2. Company Snapshot
  • 16.3.3. Products & Services
  • 16.3.4. Financials (In case of listed companies)
  • 16.3.5. Recent Developments
  • 16.3.6. SWOT Analysis
• 16.4. Novartis AG
  • 16.4.1. Business Overview
  • 16.4.2. Company Snapshot
  • 16.4.3. Products & Services
  • 16.4.4. Financials (In case of listed companies)
  • 16.4.5. Recent Developments
  • 16.4.6. SWOT Analysis
• 16.5. Pfizer Inc.
  • 16.5.1. Business Overview
  • 16.5.2. Company Snapshot
  • 16.5.3. Products & Services
  • 16.5.4. Financials (In case of listed companies)
  • 16.5.5. Recent Developments
  • 16.5.6. SWOT Analysis
• 16.6. Teva Pharmaceutical Industries Ltd.
  • 16.6.1. Business Overview
  • 16.6.2. Company Snapshot
  • 16.6.3. Products & Services
  • 16.6.4. Financials (In case of listed companies)
  • 16.6.5. Recent Developments
  • 16.6.6. SWOT Analysis
• 16.7. Bayer AG
  • 16.7.1. Business Overview
  • 16.7.2. Company Snapshot
  • 16.7.3. Products & Services
  • 16.7.4. Financials (In case of listed companies)
  • 16.7.5. Recent Developments
  • 16.7.6. SWOT Analysis
• 16.8. CLINUVEL PHARMACEUTICALS LTD
  • 16.8.1. Business Overview
  • 16.8.2. Company Snapshot
  • 16.8.3. Products & Services
  • 16.8.4. Financials (In case of listed companies)
  • 16.8.5. Recent Developments
  • 16.8.6. SWOT Analysis
• 16.9. Strides Pharma Science Limited
  • 16.9.1. Business Overview
  • 16.9.2. Company Snapshot
  • 16.9.3. Products & Services
  • 16.9.4. Financials (In case of listed companies)
  • 16.9.5. Recent Developments
  • 16.9.6. SWOT Analysis
• 16.10. Astellas Pharma Inc.
  • 16.10.1. Business Overview
  • 16.10.2. Company Snapshot
  • 16.10.3. Products & Services
  • 16.10.4. Financials (In case of listed companies)
  • 16.10.5. Recent Developments
  • 16.10.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer